PFE
PFE
$28.65
$-0.02 (-0.05%)
About
No description available for this stock.
Price History (Last 30 Days)
Latest News & Updates
The article compares two early-stage quantum technology companies: D-Wave Quantu...
The article compares two early-stage quantum technology companies: D-Wave Quantum, which has commercial customers and $24.6M in revenue but is burning cash rapidly with a -1,444% net margin, and QuantumScape, a pre-revenue solid-state battery developer with a stronger cash cushion and clearer path to commercialization. The author recommends QuantumScape as the better speculative bet due to its financial runway, despite both being high-risk moonshot investments years from profitability.
The global Enzyme Replacement Therapy (ERT) market is projected to grow from USD...
The global Enzyme Replacement Therapy (ERT) market is projected to grow from USD 12.24 billion in 2025 to USD 27.90 billion by 2035, with a CAGR of 8.59%. Growth is driven by early identification of rare lysosomal storage disorders, increased newborn screening, orphan drug incentives, and expanding healthcare access. North America leads with 38.76% market share, while Asia-Pacific shows the fastest growth at 9.43% CAGR. Imiglucerase dominates products, and Gaucher disease represents the largest therapeutic condition.
The global autoimmune disease therapeutics market is projected to grow from USD...
The global autoimmune disease therapeutics market is projected to grow from USD 133 billion in 2025 to USD 255 billion by 2034, with an 8% CAGR. Growth is driven by rising prevalence of autoimmune disorders, increasing adoption of biologics and targeted therapies, advancements in precision medicine, and expanding biosimilar availability. North America leads with 44% market share, while Asia-Pacific is the fastest-growing region. Key players include AbbVie, Johnson & Johnson, Pfizer, Novartis, and Roche.
Artificial intelligence is accelerating vaccine adjuvant discovery and optimizat...
Artificial intelligence is accelerating vaccine adjuvant discovery and optimization, with over $140M in disclosed funding signaling a structural market shift. Major investments include Pfizer and NVIDIA's $80M joint venture into CytoReason and Ginkgo Bioworks' $31M contract with SaponiQx. AI tools are addressing key bottlenecks in antigen-adjuvant optimization and immune response prediction, supported by government initiatives globally. However, regulatory fragmentation, infrastructure gaps, and a shortage of AI-immunology talent remain challenges.
The National Association of Specialty Pharmacy (NASP) recognized industry leader...
The National Association of Specialty Pharmacy (NASP) recognized industry leaders and organizations at its annual conference in National Harbor, Maryland. Award recipients included Optum Specialty Pharmacy (Specialty Pharmacy of the Year), Van Chau from UC Davis Health (Pharmacist of the Year), and Pfizer (Manufacturer of the Year), among others. The record-breaking conference attracted over 2,400 specialty pharmacy professionals.
The article compares two dividend investment strategies: Eli Lilly offers modest...
The article compares two dividend investment strategies: Eli Lilly offers modest 0.6% yield but exceptional 15.3% annual dividend growth rate and strong growth prospects in the GLP-1 market, while Pfizer provides a high 6.2% yield with sustainable dividends backed by $11 billion in free cash flow. The choice depends on investor priorities—Eli Lilly suits those seeking growth and future dividend increases, while Pfizer appeals to investors prioritizing immediate income.
A comprehensive market research report analyzing co-development deals in pharmac...
A comprehensive market research report analyzing co-development deals in pharmaceuticals and biotechnology from 2016-2026 has been released. The report covers deal structures, financial terms, the top 25 most active dealmakers, and provides access to actual SEC-filed contract documents. Co-development partnerships are highlighted as a strategic approach for companies to share R&D costs, risks, and commercial opportunities while accelerating product development timelines.
The article compares two pharmaceutical dividend stocks: AbbVie and Pfizer. AbbV...
The article compares two pharmaceutical dividend stocks: AbbVie and Pfizer. AbbVie is a Dividend King with 50+ consecutive years of dividend increases, offering a 2.6% yield and $18 billion in free cash flow, with strong growth from immunology products like Rinvoq and Skyrizi. Pfizer is in recovery mode post-pandemic, offering a higher 6.2% dividend yield but with less consistent growth. The author recommends AbbVie as the better dividend buy due to its proven ability to grow dividends sustainably and demonstrated business resilience after losing Humira exclusivity.
Bristol Myers Squibb (BMY) is up 17% this year and trades at a discount to peers...
Bristol Myers Squibb (BMY) is up 17% this year and trades at a discount to peers despite strong Q2 performance with $12.9B revenue and 153% EPS growth. The company's growth portfolio of newer drugs now accounts for nearly 60% of revenue and grew 15% year-over-year, offsetting concerns about patent expirations on legacy drugs. With a 3.95% dividend yield, $5B buyback program, and potential acquisition interest from AstraZeneca, analysts see significant upside potential as the market has underpriced the stock relative to its pipeline execution.
The article recommends three healthcare dividend stocks for long-term investors:...
The article recommends three healthcare dividend stocks for long-term investors: Pfizer, Abbott Laboratories, and Medtronic. Despite recent challenges, all three companies offer strong dividend programs with growth potential. Pfizer has a promising pipeline including weight loss and cancer drugs. Abbott benefits from a diversified medical device business and recent acquisitions. Medtronic is positioned for growth through its cardiac ablation solutions and robotic surgery systems.
